[think brie cheese + LAN party] – means: Happy Wanderer
[think brie cheese + LAN party] – means: Happy Wanderer
A year ago, I asked my network for recommendations on coaches specializing in elite athletes and transitions.
I had a few responses but nothing really hit what I was looking for and ended up going on an exploration to find the practices, tools and guidance I was seeking. Here’s what I’ve discovered so far (will update overtime):
Athlete Soul – an independent support solution for retiring athletes.
Their mission is to support athletes as they transition away from sports, raise awareness about the challenges of athletic retirement, and empower athletes to develop beyond sports.
They support athletes before, during and after their transition with educational resources, transition and career coaching, and networking opportunities.
FOUNDER & CONSULTANT – BS Strategy, Los Angeles CA (2021-present)
Consulting firm supporting initiatives and organizations that improve the health of individuals and communities.
Investment Fellowships (2022)
DIRECTOR, CROSSIX ANALYTICS SERVICES – Veeva Systems, New York NY (1/2020-11/2021)
Health-focused technology group within Veeva dedicated to advancing healthcare marketing with analytics and innovative planning, targeting, measurement, and optimization solutions.
PRINCIPAL, LIFE SCIENCES – HealthVerity, Philadelphia PA (2018-2019)
Healthtech startup focused on the discovery, licensing and linkage of data.
DIRECTOR, ACCOUNT MANAGEMENT & BUSINESS DEVELOPMENT – GNS Healthcare, Cambridge MA (2016-2018)
Big data analytics startup focused on applications of artificial intelligence and machine learning (ML) in healthcare.
MANAGER, BD STRATEGY & RESEARCH SCIENTIST – Precision Health Economics [now PrecisionHEOR], Los Angeles CA (2015-2016)
Research consulting group focused on the economic and social value of treatments and care delivery.
SENIOR RESEARCH ASSOCIATE – Mapi Group [now ICON plc], Boston MA (2012-2015)
Consulting group focused on patient-centred health outcomes research and commercialization.
RESEARCH ASSISTANT – McGill University, Department of Epidemiology and Sociology, Montreal QC (2010-2012)
Research funded by the Canadian Institute of Health Research & Canada Foundation for Innovation.
RESEARCH ASSISTANT • Centre for Clinical Epidemiology, Jewish General Hospital, Montreal QC (2010-2012)
Research funded by the Canadian Institute of Health Research.
LAB MANAGER & RESEARCH ANALYST • Arkansas Bioscience Institute, Jonesboro AR (2009- 2010)
Research funded by the U.S. Department of Defense & National Institute of Health.
M.Sc. Epidemiology – McGill University, Montreal QC, Canada (2012)
McGill University Principal Graduate Fellow
Canadian Institute of Health Research Trainee in Bridging Scientific Domains in Drug Safety and Effectiveness
Thesis: Metformin and the incidence of colorectal and lung cancer in patients with type 2 diabetes
B.S. Biological Sciences (minor chemistry) – Arkansas State University, Jonesboro AR, USA (2009)
“Who’s Who of Arkansas State University” award recipient
Sunbelt Conference All-academic Team
Semi-Professional Soccer Goalkeeper (1999-2008)
Identified as a member of the Canadian Women’s National Team player pool at age 13 and played at the highest club and university level available at that time for women in North America until retirement.
NCAA Division 1 full scholarship athlete – Arkansas State University
British Columbia Girls Provincial Tournament – Top Goaltender & 1st Team Allstar
Pacific Coast Soccer League – Women’s Challenge Cup Champion & Defender of the Game.
Canadian National Championships – Bronze medal
BC Sports Hall of Fame – Jack Farley Youth Sports Achievement Award
McDonald’s Most Valuable Player Scholarship Recipient
Long Distance Races
2019 Bare Burro 5k
2021 Los Angeles Marathon
2021 Zion National Park 1/2 Marathon
2022 Vancouver Marathon
Brassard P, et al. The effect of statins on influenza-like illness morbidity and mortality. Pharmacoepidemiology and Drug Safety, 2017;26(1):63–70.
Vieira MC, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clinical Therapeutics. 2016;38(12):2628-41.
Cope S, et al. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Medicine 2014;12:93.
Smiechowski, B, et al. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(10):1877-83.
Smiechowski, B, et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care. 2013;36(1):124-9.
Suissa D, et al. Number needed to treat is incorrect without proper time-related considerations. Journal of Clinical Epidemiology. 2012;65(1):42-6.
Latourelle J, et al. Accurate prediction of clinical disease progression in patients with advanced fibrosis due to NASH using a Bayesian machine learning approach. EASL The Liver Congress (2018).
Shrestha, A, et al. Comparative efficacy and safety of nivolumab vs relevant treatments in pretreated non-squamous advanced non-small cell lung cancer: Results from a systematic literature review and indirect treatment comparisons of randomized controlled trials. European Journal of Cancer. 2017;72(S136).
Eberhardt, WE, et al. Comparative efficacy and safety of nivolumab vs relevant treatments in pretreated squamous advanced non-small cell lung cancer: Results from a systematic literature review and indirect treatment comparisons of randomized controlled trials. European Journal of Cancer. 2017;72(S136).
Smiechowski B, Cope S. Assessing the relationship between treatment effect and baseline risk in network meta-analysis of moderate to severe chronic plaque psoriasis trials. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress (2014).
Smiechowski B, et al. Comparability of trial populations in network meta-analyses assessing biologic treatments in moderate to severe plaque psoriasis. ISPOR 19th Annual International Meeting (2014).
Cope S, et al. Comparative efficacy of everolimus in combination with exemestane and chemotherapy for advanced breast cancer in terms of progression-free survival. San Antonio Breast Cancer Symposium (2013).
Brassard P, et al. The Effect of Statins on Influenza Morbidity and Mortality. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (2013).
Buchanan R, et al. Effects of Maternal Cigarette Smoke Exposure and Methamphetamine Challenge on Brain Monoamine Concentrations in Rat Pups. Southeast IDeA Regional Meeting (2009).
Buchanan R, et al. Effects of Maternal Smoke Exposure on nAChR Subunit mRNA Expression in Brains of Peripubertal Mice. Southeast IDeA Regional Meeting (2009)
Collaborations with Arkansas State University, Arkansas Bioscience Institute, Arkansas Children’s Hospital Research Institute, University of Arkansas for Medical Sciences, Rhodes College, Radiance Technologies, and the US Space Missile Defense Command.
I had the pleasure of attending this year’s HLTH event in Las Vegas on Nov. 13-16, 2022.
#hlth2022 was the first time I had experienced an event at this scale with attendees that included more than just traditional healthcare/biotech players and investors. Attendance also included tech, consumer-focused wellness, and at a smaller capacity – patients and non-profits.
I congratulate the HLTH team for creating an event that acknowledges how we approach health is changing and that the tools and systems necessary to allow everyone the opportunity to be healthy goes beyond what health insurance traditionally covers. I hope the conversations at HLTH lead to more common language and openness for alignment on the scientific rigour necessary for a consumer product to be taken seriously by traditional health players.
Connecting key health stakeholders from diverse backgrounds is a significant step in the right direction, redefining what is considered “healthcare” and who pays for what is needed. Although consumer and retail products have value, affordability is still an issue, especially if payers are not considering these offerings for reimbursement. Many valuable solutions may never reach those who need them most due to the inability to pay out of pocket.
Further, more efforts are required to help improve benefits communication, patient and caregiver education, benefits communication, and guidance around coordinating whole health care. As discussed during the Sexual Healing panel – language matters – we need to meet individuals where they are. Creating complicated reimbursement schemes or unclear patient pathways further deters the engagement of high-need but historically marginalized individuals.
Reimaging healthcare requires greater awareness and more conversations around the inequities and barriers to access that exist to being healthy. I was happy to hear many talks at HTLH discuss inclusion, health equity and social determinants of health (SDOH). However, I found that much of the heavy lifting and progress around these initiatives still comes from female and minority-led start-ups, non-profits and government. Big healthcare, life sciences and tech need to step up and better support efforts through partnerships, acquisitions, and funding versus building lacklustre duplicates or “check the box on DEI” solutions.
For start-ups and capital providers, HTLH also confirmed that a course correction in funding is occurring. Although many blame COVID for creating a funding ecosystem that led to waste and significantly overvalued start-ups, this trend was already apparent in mid-2019. COVID only added fuel to this unfortunate trend.
I stepped away from consulting with digital health start-ups at the end of 2019 due to my frustration of encountering many organizations that had raised significant funds but were not incentivized or interested in genuinely moving the needle in healthcare. Instead, many start-ups chose to take the consumer route to hit early funding milestones. At this time, I opted to join Veeva for 2 years, a rare example of a Healthtech start-up that raised minimal cash ($7M total) and reached $1 billion in yearly revenue within thirteen years of its inception.
Moving forward, I hope fundraising becomes more intentional and investors take the time to build relationships with entrepreneurs and organizations closely tied to the communities they claim to serve. Further, due diligence needs to focus on more than just financial returns. Considering clinical outcomes, societal impact and addressing unmet needs are also important.
I commend HLTH for providing a platform for many aspects of health, including nutrition, sleep, sexual, mental and dental health. I also appreciate the diverse representation of individuals involved and impacted by the health industry, including rural communities, providers, caregivers, incarcerated individuals and athletes.
Thank you, CoverMyMeds, for the fantastic beauty station, Carrot Fertility for their free headshots, and for Brightside Health (I believe) for providing a hammock for an epic mid-event nap.
Where I struggled at HTLH was how much of the focus of networking and connection was around the consumption of alcohol and unhealthy food. I appreciate that there was a group exercise option offered early on Monday and Tuesday morning and some “wellness” features throughout the event. I would love to see more activities, happy hours and networking opportunities beyond drinks and mingling. I am happy to connect with any organizations interested in exploring this (check out Eat Move Meditate for inspiration).
Thank you, Jerrica Kirkley from Plume, ScaleHealth, Redesign Health, Samsung Next, Komodo Health, and Paytient, for your hospitality and for creating space for intentional connection. Thank you to Matthew Holt, Melissa Faukner and the UCSF Health Hub Digital Health Awards team for helping me with my ticket.
I am grateful for the many insightful conversations with incredibly thoughtful and inspiring individuals throughout my time at HLTH.
Here’s to creating an abundance of intentional partnerships and collaborations in 2023 that allow for improved quality of life for all individuals and decrease the burden and cost of illness on society.
University of Southern California, School of Pharmacy (2016- Present)
Guest Lecturer: MS in Healthcare Decision Analysis Program
HCDA 525: Healthcare Literature Analysis and Applications (2016, 18, 19, 21)
HCDA 502: Comparative International Healthcare System (2018)
Guest Lecturer: BS in Biopharmaceutical Sciences Program
BPSI 411: Biopharmaceutical Marketing Analysis and Strategy (2022)
Core Topics: clinical trial, epidemiology and health economic study design, drug development, commercialization and marketing. How to navigate peer-reviewed research. How to identify and assess scientific studies and literature, research synthesis and dissemination.
New Technology Venture Accelerator (NETVA), Consulate General of France & UCLA Anderson Venture Accelerator (2022)
Speaker: Healthcare Fundraising in the United States
BioscienceLA & Netherlands Business Delegation Life Sciences & Health (2022)
Roundtable Leader: Healthcare Investors & Accelerators in the United States
Microsoft Canada (2022)
Speaker: Data-Driven Decision-Making for Health Equity & Impact
Canadian Institute of Health Research (2021)
Panelist: DSECT Symposium Alumni Panel
AnitaB.org LA Women in Tech (2019)
Panelist: Career Management Panel Discussion. The Importance of Sponsorship & Mentoring with Tech Leaders
University of Southern California (2017)
Panelist: Future of Healthcare – How Machine Learning is Shaping the Future of Healthcare
GNS Healthcare Blog (2018)
Author: Real World Evidence: How It’s Changing the Way Drugs are Developed and Valued
Thrillist Health (2016)
Contributor: Secrets that get you the cheapest prescription drugs every time